- Home
- KRP vs IMTX Comparison
KRP vs IMTX Comparison
Compare KRP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- IMTX
- Stock Information
- Founded
- KRP 2013
- IMTX N/A
- Country
- KRP United States
- IMTX Germany
- Employees
- KRP N/A
- IMTX N/A
- Industry
- KRP Oil & Gas Production
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRP Energy
- IMTX Health Care
- Exchange
- KRP Nasdaq
- IMTX Nasdaq
- Market Cap
- KRP 1.3B
- IMTX 1.1B
- IPO Year
- KRP 2017
- IMTX N/A
- Fundamental
- Price
- KRP $16.16
- IMTX $9.54
- Analyst Decision
- KRP Strong Buy
- IMTX Strong Buy
- Analyst Count
- KRP 5
- IMTX 3
- Target Price
- KRP $19.60
- IMTX $17.50
- AVG Volume (30 Days)
- KRP 375.6K
- IMTX 766.4K
- Earning Date
- KRP 11-07-2024
- IMTX 11-12-2024
- Dividend Yield
- KRP 10.38%
- IMTX N/A
- EPS Growth
- KRP N/A
- IMTX N/A
- EPS
- KRP 0.49
- IMTX N/A
- Revenue
- KRP $321,860,199.00
- IMTX $75,935,926.00
- Revenue This Year
- KRP $19.99
- IMTX $44.87
- Revenue Next Year
- KRP $6.97
- IMTX N/A
- P/E Ratio
- KRP $33.23
- IMTX N/A
- Revenue Growth
- KRP 25.54
- IMTX N/A
- 52 Week Low
- KRP $14.26
- IMTX $7.15
- 52 Week High
- KRP $17.11
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- KRP 51.71
- IMTX 34.58
- Support Level
- KRP $16.05
- IMTX $9.18
- Resistance Level
- KRP $16.28
- IMTX $9.95
- Average True Range (ATR)
- KRP 0.20
- IMTX 0.44
- MACD
- KRP -0.02
- IMTX -0.05
- Stochastic Oscillator
- KRP 31.54
- IMTX 16.96
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.